CE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CE is not a strong buy right now for a beginner with a long-term horizon, despite some favorable analyst upgrades. The stock has short-term technical support and positive option sentiment, but the latest quarter showed weaker fundamentals and there is no clear AI Stock Picker or SwingMax signal. If the investor wants immediate action and is unwilling to wait for a better entry, this is still more of a hold than a buy today.
Price is 67.53, basically near the R1 resistance at 67.657 and above the pivot at 64.979, which shows the stock has recovered well. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, so the trend is constructive. However, MACD histogram is still negative at -0.212, meaning momentum is not fully confirmed. RSI_6 at 68.594 is close to overbought territory, so upside may be near-term limited rather than an ideal fresh entry.
Analyst sentiment has improved meaningfully, with multiple firms raising targets and several maintaining Buy/Overweight views. BofA, Citi, Wells Fargo, Baird, and RBC all turned more constructive, citing tighter supply, commodity price support, and improved value capture in acetyls. The chart trend is bullish across key moving averages, and the stock has a favorable short-term pattern with a modest upside bias. Earnings are coming up on 2026-05-05 after hours, which could act as a catalyst if results beat low expectations.
Recent news flow is quiet, so there is no fresh event-driven support from headlines. The latest quarter was weak: revenue fell 6.53% YoY, net income collapsed, EPS dropped sharply, and gross margin contracted. MACD remains negative, suggesting momentum is not fully resolved. There is no recent AI Stock Picker or SwingMax signal to reinforce an immediate aggressive entry. Hedge funds and insiders are neutral, and there is no recent congress or politician trading activity.
In 2025/Q4, Celanese showed weaker operating performance. Revenue declined to $2.204B, down 6.53% YoY, while net income fell to $19M, EPS dropped to $0.17, and gross margin declined to 17.38%. That points to margin pressure and earnings softness, so the latest quarter does not yet support a strong long-term fundamental buy on its own.
Analyst sentiment has trended more positive over the last month. Targets were raised by BofA to $75, Citi to $84, Wells Fargo to $75, RBC to $66, UBS to $64, Mizuho to $58, and Baird to $75. The Wall Street bull case is that tighter supply, higher commodity prices, and Celanese’s acetyls exposure should improve earnings and value capture. The bear/neutral view is that end markets remain challenged and the latest fundamentals are still weak, so while pros are more constructive, the stock is not a clean consensus buy.
